Anzeige
Mehr »
Login
Montag, 15.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Im Fokus der Anleger: InnoCan Pharma vor entscheidendem Meilenstein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QHYP | ISIN: US89422G1076 | Ticker-Symbol: 17R
Berlin
15.04.24
20:30 Uhr
5,850 Euro
-0,200
-3,31 %
1-Jahres-Chart
TRAVERE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TRAVERE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur TRAVERE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
04.04.Travere Therapeutics, Inc.: Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International1
03.04.Travere Therapeutics, Inc.: Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association2
13.03.Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)47SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted inducement...
► Artikel lesen
11.03.Travere Therapeutics, Inc.: Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN)297SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration...
► Artikel lesen
29.02.CHMP recommends Travere and CSL Vifor's Filspari to treat rare kidney disease IgAN4
26.02.Travere Therapeutics, Inc.: Travere Therapeutics to Present at Upcoming Investor Conferences1
23.02.Travere Therapeutics, Inc. - 8-K, Current Report1
23.02.Travere's Filspari, J&J's Carvykti win support from CHMP in blitz of positive recommendations3
23.02.Travere climbs after kidney drug gets recommended for EU approval-
23.02.Travere Therapeutics, Inc.: Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy2
23.02.Travere Therapeutics gains as EU backs kidney disease therapy1
23.02.CSL, Travere close on EU approval of IgAN drug sparsentan-
23.02.Travere drug for rare kidney condition recommended for EU approval2
23.02.Vifor International AG (CSL Vifor): CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy230Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive...
► Artikel lesen
20.02.Travere Therapeutics, Inc. - 10-K, Annual Report2
16.02.Earnings call: Travere Therapeutics reports Q4 and full-year 2023 results3
16.02.Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings)3
15.02.Travere Therapeutics Non-GAAP EPS of $0.94 beats by $1.86, revenue of $45.05M beats by $3.23M1
15.02.Travere Therapeutics, Inc.: Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results142Received 459 new patient start forms (PSFs) for FILSPARI® (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S. accelerated approval...
► Artikel lesen
15.02.Travere Therapeutics, Inc. - 8-K, Current Report1
Seite:  Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1